Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARGARET VON MEHREN

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1144243858
CMS profile
233516
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,481.32

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,480.00 2
Food and Beverage $1.32 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Exelixis Inc. $1,980.00 1
PFIZER INC. $1,501.32 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARGARET VON MEHREN

NPI 1144243858 · CMS profile ID 233516

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARGARET VON MEHREN, NPI 1144243858, CMS profile ID 233516, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1144243858?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $3,481.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Exelixis Inc. $1,980.0005/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686543021 CMS
PFIZER INC. $1,500.0001/17/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673757429 CMS
PFIZER INC. $1.3201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673262617 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,481.32 3
PY2022 $16,889.37 14
PY2024 $17,850.01 21
PY2025 $107.49 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $439.96 2
PY2025 Principal investigator $3,999,133.04 151
PY2024 Principal investigator $2,114,235.16 59
PY2023 Principal investigator $1,626,861.83 207
PY2022 Recipient $12,046.00 1
PY2022 Principal investigator $1,964,612.75 261
PY2021 Principal investigator $4,056,403.36 219
PY2020 Recipient $1,210.00 1
PY2020 Principal investigator $2,320,213.22 69
PY2019 Principal investigator $1,242,313.06 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

219 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 12/28/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827901551
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,122.00 12/28/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827901589
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,584.00 12/28/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827901603
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,584.00 12/28/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827901619
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,122.00 12/28/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827901623
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 12/28/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827901641
Principal investigator 1 Deciphera Pharmaceuticals Inc. $111,900.00 12/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900323
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,278.00 12/09/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961942043
Principal investigator 1 Deciphera Pharmaceuticals Inc. $201,420.00 11/16/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885851
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900009
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900033
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900035
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900057
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900061
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900071
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900091
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900093
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900109
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900155
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900171
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900189
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900191
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 11/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827900207
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,831.38 10/30/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885847
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,000.00 10/30/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885849
Principal investigator 1 Karyopharm Therapeutics Inc. $713.20 10/29/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
A Phase 2-3 Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) versus Placebo in Patients with Advanced Unresectable Dedifferentiated Liposarcoma (DDLS) No dispute reported 06/30/2026 845834029
Principal investigator 1 Deciphera Pharmaceuticals Inc. $111,900.00 10/28/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827899621
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,556.00 10/28/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941987
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,123.00 10/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827899385
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,621.00 10/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827899407
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,123.00 10/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827899459
Principal investigator 1 Deciphera Pharmaceuticals Inc. $67,140.00 09/28/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827899196
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,139.00 09/28/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941939
Principal investigator 1 Blueprint Medicines Corporation $6,204.00 09/27/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors No dispute reported 06/30/2026 848927689
Principal investigator 1 Deciphera Pharmaceuticals Inc. $67,140.00 09/23/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885845
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,584.00 09/21/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898949
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 09/21/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898959
Principal investigator 1 Novartis Pharmaceuticals Corporation $337,097.60 09/15/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
AN OPEN LABEL MULTI CENTER IMATINIB ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED IMATINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED IMATINIB TREATMENT No dispute reported 06/30/2026 800631503
Principal investigator 1 Blueprint Medicines Corporation $26,173.52 09/09/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 848927157
Principal investigator 1 Blueprint Medicines Corporation $102.68 09/09/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 848927159
Principal investigator 1 Blueprint Medicines Corporation $22.30 09/09/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 848927161
Principal investigator 1 Blueprint Medicines Corporation $21.59 09/09/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 848927163
Principal investigator 1 Blueprint Medicines Corporation $54.22 09/09/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 848927165
Principal investigator 1 Blueprint Medicines Corporation $59.58 09/09/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) No dispute reported 06/30/2026 848927167
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,584.00 09/04/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898695
Principal investigator 1 Blueprint Medicines Corporation $7,500.00 08/23/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors No dispute reported 06/30/2026 848927685
Principal investigator 1 Blueprint Medicines Corporation $2,000.00 08/23/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors No dispute reported 06/30/2026 848927687
Principal investigator 1 Deciphera Pharmaceuticals Inc. $111,900.00 08/05/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898443
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,556.00 08/05/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941909
Principal investigator 1 Deciphera Pharmaceuticals Inc. $302,130.00 07/27/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885843
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827897949
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,524.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827897997
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,526.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898039
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898043
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898049
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898069
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898107
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,524.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898129
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,584.00 07/16/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827898171
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885697
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885699
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885701
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,205.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885703
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885705
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885707
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885709
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885711
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885713
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885715
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885717
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885719
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,831.38 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885721
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885723
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885725
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885727
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885729
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885731
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885733
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885735
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885737
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885739
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885741
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885745
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885747
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885749
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885751
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885753
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885755
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885757
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885759
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885761
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885763
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885765
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885767
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885769
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885771
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885773
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885775
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885777
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885779
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885781
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885783
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885785
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885787
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885789
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885791
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885793
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885795
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885797
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885799
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885801
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885803
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885805
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,205.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885807
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885809
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885811
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885813
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885815
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885817
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885819
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885821
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885823
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885825
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885827
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885829
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885831
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885833
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885835
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885837
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885839
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 07/07/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885841
Principal investigator 1 Deciphera Pharmaceuticals Inc. $202,666.73 06/24/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885695
Principal investigator 1 Deciphera Pharmaceuticals Inc. $106,666.67 06/24/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827897281
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,556.00 06/24/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941835
Principal investigator 1 Blueprint Medicines Corporation $46,346.00 06/21/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors No dispute reported 06/30/2026 848927679
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,082.00 06/11/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827897205
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,123.00 06/11/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827897213
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896969
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896971
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896973
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896975
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896977
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,250.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896981
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896983
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896989
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827896991
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897001
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897005
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897007
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897009
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897011
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897013
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897017
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897019
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897021
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,501.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897023
Principal investigator 1 Deciphera Pharmaceuticals Inc. $500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897031
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 06/08/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS WHO HAVE RECEIVED TREATMENT WITH PRIOR ANTICANCER THERAPIES No dispute reported 06/30/2026 827897033
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 05/22/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885687
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 05/22/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885689
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 05/22/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885691
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 05/22/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885693
Principal investigator 1 Deciphera Pharmaceuticals Inc. $213,333.40 05/21/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885685
Principal investigator 1 Deciphera Pharmaceuticals Inc. $53,333.33 05/19/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827896817
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,556.00 05/19/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941774
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885659
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885661
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885663
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885665
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885667
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885669
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885671
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885673
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885675
Principal investigator 1 Deciphera Pharmaceuticals Inc. $160,000.05 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885677
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885679
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885681
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,500.00 05/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885683
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,584.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895319
Principal investigator 1 Deciphera Pharmaceuticals Inc. $454.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895367
Principal investigator 1 Deciphera Pharmaceuticals Inc. $454.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895399
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,062.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895401
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,585.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895489
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,062.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895607
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,123.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895619
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895625
Principal investigator 1 Deciphera Pharmaceuticals Inc. $322.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895669
Principal investigator 1 Deciphera Pharmaceuticals Inc. $454.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895675
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,000.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895693
Principal investigator 1 Deciphera Pharmaceuticals Inc. $454.00 04/09/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827895757
Principal investigator 1 Deciphera Pharmaceuticals Inc. $138,666.71 04/06/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885657
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 04/03/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885643
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 04/03/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885645
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 04/03/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885647
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 04/03/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885649
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 04/03/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885651
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,000.00 04/03/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885653
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,742.30 04/03/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885655
Principal investigator 1 Deciphera Pharmaceuticals Inc. $160,000.00 03/24/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827894475
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,112.00 03/24/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941683
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,112.00 03/24/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941691
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,535.00 03/05/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827894215
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,549.00 03/05/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827894249
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,204.00 03/05/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827894309
Principal investigator 1 Blueprint Medicines Corporation $15,577.25 02/25/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 848927091
Principal investigator 1 Blueprint Medicines Corporation $15,517.75 02/25/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 848927093
Principal investigator 1 Deciphera Pharmaceuticals Inc. $202,666.73 02/25/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885641
Principal investigator 1 Deciphera Pharmaceuticals Inc. $170,666.72 02/10/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885639
Principal investigator 1 Deciphera Pharmaceuticals Inc. $160,000.00 02/10/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827893985
Principal investigator 1 Deciphera Pharmaceuticals Inc. $8,224.00 02/10/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941609
Principal investigator 1 Blueprint Medicines Corporation $5,030.00 02/04/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 848927089
Principal investigator 1 Blueprint Medicines Corporation $13,326.53 02/04/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 848927095
Principal investigator 1 Blueprint Medicines Corporation $7,580.71 02/04/2021 Non-covered Recipient Entity
INSTITUTE FOR CANCER RESEARCH
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy No dispute reported 06/30/2026 848927097
Principal investigator 1 Blueprint Medicines Corporation $3,662.00 01/25/2021 Covered Recipient Teaching Hospital
American Oncologic Hospial
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors No dispute reported 06/30/2026 848927677
Principal investigator 1 Deciphera Pharmaceuticals Inc. $311.78 01/22/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885637
Principal investigator 1 Deciphera Pharmaceuticals Inc. $202,666.73 01/13/2021 Covered Recipient Teaching Hospital
AMERICAN ONCOLOGIC HOSPIAL
A SAFETY TOLERABILITY AND PK STUDY OF DCC-2618 IN PATIENTS WITH ADVANCED MALIGNANCIES No dispute reported 06/30/2026 827885635
Principal investigator 1 Novartis Pharmaceuticals Corporation $240,259.52 01/07/2021 Non-covered Recipient Entity
DANAFARBER CANCER INSTITUTE
PHASE II TRIAL OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS IN ADVANCED DEDIFFERENTIATED LIPOSARCOMA DDL AND LEIOMYOSARCOMA LMS No dispute reported 06/30/2026 800629633
Principal investigator 1 Deciphera Pharmaceuticals Inc. $160,000.00 01/05/2021 Non-covered Recipient Entity
THE AMERICAN ONCOLOGIC HOSPITAL DBA HOSPITAL OF THE FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 827893611
Principal investigator 1 Deciphera Pharmaceuticals Inc. $7,400.00 01/05/2021 Non-covered Recipient Entity
FOX CHASE CANCER CENTER
INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE No dispute reported 06/30/2026 961941485